Indivior (NASDAQ:INDV) Director Purchases $27,427.25 in Stock

Indivior PLC (NASDAQ:INDV) Director Mark Stejbach bought 775 shares of the company’s stock in a transaction on Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the transaction, the director owned 16,847 shares in the company, valued at approximately $596,215.33. The trade was a 4.82% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Indivior Stock Performance

Shares of NASDAQ INDV traded down $0.35 during trading hours on Wednesday, hitting $35.85. The stock had a trading volume of 1,097,072 shares, compared to its average volume of 1,460,802. The firm’s 50-day moving average price is $33.69 and its two-hundred day moving average price is $25.59. Indivior PLC has a 52 week low of $7.62 and a 52 week high of $38.00. The company has a market capitalization of $4.48 billion, a P/E ratio of 38.96 and a beta of 0.75.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.34. The firm had revenue of $314.00 million for the quarter, compared to analyst estimates of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. As a group, analysts expect that Indivior PLC will post 1.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Indivior

A number of institutional investors have recently made changes to their positions in INDV. GAMMA Investing LLC lifted its position in shares of Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares during the last quarter. Goldentree Asset Management LP acquired a new stake in Indivior in the 3rd quarter valued at approximately $42,630,000. CIBC Bancorp USA Inc. bought a new position in Indivior in the 3rd quarter worth approximately $312,000. Jacobs Levy Equity Management Inc. bought a new position in Indivior in the 3rd quarter worth approximately $33,496,000. Finally, Woodline Partners LP acquired a new position in shares of Indivior during the third quarter worth approximately $6,413,000. 60.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on INDV. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, November 3rd. Northland Securities set a $40.00 price target on Indivior in a research note on Friday, October 31st. HC Wainwright increased their price objective on Indivior from $28.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Craig Hallum reissued a “buy” rating and issued a $41.00 price objective on shares of Indivior in a research note on Friday, October 31st. Finally, Piper Sandler restated an “overweight” rating and issued a $41.00 target price (up from $27.00) on shares of Indivior in a report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $32.71.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.